Skip to main
VCEL
VCEL logo

Vericel (VCEL) Stock Forecast & Price Target

Vericel (VCEL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vericel Corp is positioned for sustainable revenue growth, particularly with its flagship product MACI, which is anticipated to experience a volume growth of approximately 14.8% compounded annually, driven by increasing market penetration. Additionally, the average selling prices (ASPs) for MACI are projected to rise by 300 to 500 basis points annually, further enhancing revenue potential. Overall, these factors suggest a robust outlook for MACI's top-line growth, with estimates indicating a year-over-year increase in the high teens to low twenties by fiscal year 2026.

Bears say

The outlook on Vericel Corp's stock is negatively impacted by a reduction in expected revenues from its MACI product for fiscal years 2026 and 2027, with a decrease of approximately 200 basis points projected. Potential risks further compound this negativity, as there are concerns regarding lower adoption rates for MACI Arthro, slower growth in burn care sales, and possible disruptions associated with the expansion of the sales force. Additionally, uncertainties surrounding physician adoption of MACI and MACI Arthro, variable demand for Epicel, and the possibility of delays in NexoBrid's approval contribute to broader concerns regarding the company's revenue trajectory.

Vericel (VCEL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vericel (VCEL) Forecast

Analysts have given Vericel (VCEL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Vericel (VCEL) has a Strong Buy consensus rating as of Oct 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vericel (VCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.